[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

622A.O3.6 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Clinical Determinants and Microenvironment

Program: Oral and Poster Abstracts
Type: Oral
Tuesday, December 13, 2011: 7:30 AM-9:00 AM
Room 5AB (San Diego Convention Center)
Alfred Reiter, MD, Justus-Liebig-University , Claudia Rossig, MD, University Children's Hospital Muenster and Stephen James Simko III, MD, Texas Children's Hospital

No relevant conflicts of interest to declare.
7:30 AM
The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study

Carlo Visco, MD1*, Alexander Tzankov, MD2*, Zijun Y. Xu-Monette, PhD3*, Roberto N. Miranda, MD3, Emanuele S. G. d'Amore, MD4*, Santiago Montes-Moreno, MD5*, Karen Dybkaer, PhD6*, April Chiu, MD7*, Wayne Tam, MD, PhD8, Attilio Orazi, MD9*, Youli Zu, MD, PhD10, Govind Bhagat, MD11, Brad S. Kahl, MD12, Jane N. Winter, MD13, Huan-You Wang, MD, PhD14*, Cherie H. Dunphy, MD15*, Eric D. Hsi, MD16, Frank X. Zhao, MD, PhD17*, Ronald S. Go, MD18, William W. L. Choi, MD19*, Fan Zhou, MD, PhD20, Magdalena Czader, MD, PhD21*, Xiaoying Zhao, MD22*, Joannes H.J.M. Van Krieken, PhD, MD23, Qin Huang, MD, PhD24, Weiyun Ai, MD, PhD25, Joan E. Etzell, MD26, Maurilio Ponzoni, MD27, Andres J.M. Ferreri, MD28, Miguel A. Piris, MD29*, Michael B. Møller, MD, PhD30*, Carlos E. Bueso-Ramos, MD, PhD31, L. Jeffrey Medeiros, MD3 and Ken H. Young, MD3

1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, and San Bortolo Hospital, Vicenza, Italy
2Department of Pathology, University Hospital of Basel, Basel, Switzerland
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Pathology, San Bortolo Hospital, Vicenza, Italy
5Department of Pathology, Hospital Universitario Marques de Valdecilla, Santander, Spain
6Department of Haematology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
7Department of Pathology, Brigham and Women Hospital, Harvard Medical School, Boston, MA
8Department of Pathology, Weill Cornell Medical College, New York, NY
9Department of Pathology & Laboratory Medicine, Weill Cornell Medical College, New York, NY
10Department of Pathology, The Methodist Hospital, Houston, TX
11Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY
12Department of Medicine-Hematology/Oncology, University of Wisconsin, Madison, WI
13Department of Medicine-Hematology/Oncology, Feinberg School of Medicine, Northwester University, Chicago, IL
14Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA
15Department of Pathology, University of North Carolina, Chapel Hill, NC
16Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH
17Department of Pathology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
18Center for Cancer and Blood Disorders, Gundersen Lutheran Health System, La Crosse, WI
19Department of Pathology, University of Hong Kong, Hong Kong, China
20Department of Pathology, Southwest Washington Medical Center, Vancouver, WA
21Department of Pathology, Indiana University Cancer Center, Indianapolis, IN
22Department of Medicine-Hematology/Oncology, Zhejiang University School of Medicine, Second University Hospital, Hangzhou, China
23Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
24Department of Pathology, City of Hope National Medical Center, Duarte, CA
25Department of Medicine-Hematology/Oncology, University of California at San Francisco, San Francisco, CA
26Department of Pathology, University of California at San Francisco, San Francisco, CA
27Pathology Unit and Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy
28Department of Medicine-Hematology/Oncology, San Raffaele H. Scientific Institute, Milan, Italy
29Servicio de Anatomía Patológica, Hospital Universitario Marques de Vadecilla, Santander, Spain
30Department of Pathology, Odense University Hospital, Odense, Denmark
31Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

7:45 AM
Cell of Origin Determination in Diffuse Large B-Cell Lymphoma: Performance of Immunohistochemical (IHC) Algorithms and Ability to Predict Outcome

Brian T. Hill, MD, PhD1, Angela M.B. Collie, M.D,, Ph.D.2*, Tomas Radivoyevitch, PhD3*, Eric D. Hsi, MD4 and John Sweetenham, M.D.5

1Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland , OH
3Department of Epidemiology and Biostatistics, Case Western University, Cleveland, OH
4Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH
5Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

8:00 AM
Exploring the Immune Microenvironment of Diffuse Large B Cell Lymphoma in a Tissue Microarray: Predicting Survival with a Score That Incorporates Macrophages, Cytotoxic and Regulatory T Cells

Rita Coutinho*, Andrew James Clear, BSc*, David Andrew Owen*, Paul Greaves*, Simon L. Hallam*, Andrew Wilson*, Janet Matthews*, Maria Calaminici, MD* and John G. Gribben, MD, DSc

Centre for Haemato-Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University, London, United Kingdom

8:15 AM
CXCR4 Antagonist BKT140 Synergizes with Rituximab, Targeting Non Hodgkin Lymphoma (NHL) In Vitro and In Vivo in a Xenograft Model with Bone Marrow Involvement

Katia Beider1*, Elena Ribakovsky1*, Michal Abraham2*, Hanna Wald2*, Orly Eizenberg2*, Abraham Avigdor, MD1, Amnon Peled, PhD3* and Arnon Nagler1

1Hematology Division, Chaim Sheba Medical Center and Tel Aviv University, Guy Weinshtock Multiple Myeloma Foundation, Tel-Hashomer, Israel
2Biokine Therapeutics Ltd, Ness Ziona, Israel
3Goldyne Savad Institute of Gene Therapy, Jerusalem, Israel

8:30 AM
Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms’ Tumor Antigen in Patients with Non-Hodgkin Lymphoma

Ryotaro Nakamura, MD1, Anna Israyelyan, MD, PhD2*, Corinna La Rosa, PhD2*, Weimin Tsai, BS1*, Teodora Kaltcheva, PhD3*, Tumul Srivastava, PhD2*, Jessica Lo, BS2*, Lia Aquino4*, Jianqiang Li, PhD2*, Young Kim, MD5, Joycelynne Palmer, PhD6*, David Senitzer, PhD1, John Zaia, MD7*, Stephen J. Forman, MD1 and Don J. Diamond, PhD2

1Department of Hematology/HCT, City of Hope , Duarte, CA
2Division of Translational Vaccine Research, City of Hope, Duarte, CA
3Division of Translational Vaccine Research, City of Hope, Duarte , CA
4Division of Biostatistics, City of Hope, Duarte, CA
5Department of Pathology, City of Hope , Duarte, CA
6Division of Biostatistics, City of Hope , Duarte, CA
7Department of Virology, City of Hope , Duarte, CA

8:45 AM
Egress of CD19+CD5+ Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor,  PCI-32765,  in Mantle Cell Lymphoma Patients

Betty Y Chang, PhD1*, Michelle Francesco1*, Padmaja Magadala1*, Min Mei Huang, PhD1, Marcel Spaargaren, PhD2*, Joseph J. Buggy, PhD1* and Laurence Elias, MD1

1Research, Pharmacyclics, Sunnyvale, CA
2Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

*signifies non-member of ASH